Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Arthur T. Sands
Person

Arthur T. Sands

Tracked across 3 events · 34 articles · First seen Jun 07, 2026 · Last active Aug 04, 2026

Sentiment
23
Attention
8
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (3)
8 70
Business
Roche Licenses Nurix Therapeutics' Bexobrutideg
Impact: Arthur T. Sands, CEO of Nurix Therapeutics, emphasized that the partnership with Roche is crucial for translating the promise of targeted protein degradation into global patient impact and extending bexobrutideg's therapeutic opportunities.
Jun 07, 2026 · 22 articles
4 0
Tech
Nurix Enrolls First Patient in Phase 3 CLL Trial
Impact: As CEO, Sands is a key spokesperson and his leadership is tied to the company's progress.
Aug 04, 2026 · 6 articles
4 0
Business
Nurix-Roche bexobrutideg collaboration closed
Impact: As CEO of Nurix, Sands announced the closing and expressed optimism about the collaboration's potential.
Jul 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Arthur T. Sands live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.